New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain
Lonza boosts TheraPEAK line with new Cytokines and AAV Medium for next-gen therapies
Maria Soler Nunez appointed as Chief Quality Officer
Upgrades 2025 full-year CDMO sales and margin outlook
Centre for Continuous Manufacturing and Advanced Crystallisation (CMAC) aims to accelerate the digital transformation of CMC development and manufacturing approaches
Lonza’s new simplified and streamlined operating model is designed to support its One Lonza vision and strategy
Lonza to develop spray-dried formulations for an intranasally-delivered biologic for Iconovo at its Center of Excellence for bioavailability enhancement and inhaled delivery in Bend (US)
New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari and Suzhou
The CDMO business will be structured into three new business platforms designed to create a unified organization: Integrated Biologics, Advanced Synthesis, and Specialized Modalities
First GMP batch released at Lonza’s next-generation mammalian manufacturing facility in Portsmouth (US)
Subscribe To Our Newsletter & Stay Updated
